Interaction Between -VS Heterozygosity and ε4 Allele Predicts Rate of Cognitive Decline in Late-Onset Alzheimer's Disease

Overview

Journal Genes (Basel)

Publisher MDPI

Date 2023 Apr 28

PMID 37107675

Authors

Xi Richard Chen

Yongzhao Shao

Martin J Sadowski

The Alzheimers Disease Neuroimaging Initiative

Affiliations

Soon will be listed here.

Abstract

-VS heterozygosity (-VS) promotes longevity and protects against cognitive decline in aging. To determine whether -VS mitigates Alzheimer's disease (AD) progression, we used longitudinal linear-mixed models to compare the rate of change in multiple cognitive measures in AD patients stratified by carrier status. We aggregated data on 665 participants (208 -VS/, 307 -VS/, 66 -VS/, and 84 -VS/) from two prospective cohorts, the National Alzheimer's Coordinating Center and the Alzheimer's Disease Neuroimaging Initiative. All participants were initially diagnosed with mild cognitive impairment, later developed AD dementia during the study, and had at least three subsequent visits. -VS conferred slower cognitive decline in non-carriers (+0.287 MMSE points/year, = 0.001; -0.104 CDR-SB points/year, = 0.026; -0.042 ADCOMS points/year, < 0.001) but not in carriers who generally had faster rates of decline than non-carriers. Stratified analyses showed that the protective effect of -VS was particularly prominent in male participants, those who were older than the median baseline age of 76 years, or those who had an education level of at least 16 years. For the first time, our study provides evidence that -VS status has a protective effect on AD progression and interacts with the allele.

Citing Articles

Lower mortality risk in APOE4 carriers with normal cognitive ageing.

Pirraglia E, Glodzik L, Shao Y Sci Rep. 2023; 13(1):15089.

PMID: 37699966 PMC: 10497512. DOI: 10.1038/s41598-023-41078-5.

References

Holland D, Desikan R, Dale A, McEvoy L . Higher rates of decline for women and apolipoprotein E epsilon4 carriers. AJNR Am J Neuroradiol. 2013; 34(12):2287-93. PMC: 3894062. DOI: 10.3174/ajnr.A3601. View

Selkoe D, Hardy J . The amyloid hypothesis of Alzheimer's disease at 25 years. EMBO Mol Med. 2016; 8(6):595-608. PMC: 4888851. DOI: 10.15252/emmm.201606210. View

Xu W, Yu J, Tan M, Tan L . Cognitive reserve and Alzheimer's disease. Mol Neurobiol. 2014; 51(1):187-208. DOI: 10.1007/s12035-014-8720-y. View

Li H, Wang B, Wang Z, Guo Q, Tabuchi K, Hammer R . Soluble amyloid precursor protein (APP) regulates transthyretin and Klotho gene expression without rescuing the essential function of APP. Proc Natl Acad Sci U S A. 2010; 107(40):17362-7. PMC: 2951422. DOI: 10.1073/pnas.1012568107. View

Frieden C, Wang H, Ho C . A mechanism for lipid binding to apoE and the role of intrinsically disordered regions coupled to domain-domain interactions. Proc Natl Acad Sci U S A. 2017; 114(24):6292-6297. PMC: 5474821. DOI: 10.1073/pnas.1705080114. View

Hobel Z, Isenberg A, Raghupathy D, Mack W, Pa J . APOEɛ4 Gene Dose and Sex Effects on Alzheimer's Disease MRI Biomarkers in Older Adults with Mild Cognitive Impairment. J Alzheimers Dis. 2019; 71(2):647-658. PMC: 6839478. DOI: 10.3233/JAD-180859. View

Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira M, Bender D . PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet. 2007; 81(3):559-75. PMC: 1950838. DOI: 10.1086/519795. View

Kuro-o M, Matsumura Y, Aizawa H, Kawaguchi H, Suga T, Utsugi T . Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature. 1997; 390(6655):45-51. DOI: 10.1038/36285. View

Abraham C, Mullen P, Tucker-Zhou T, Chen C, Zeldich E . Klotho Is a Neuroprotective and Cognition-Enhancing Protein. Vitam Horm. 2016; 101:215-38. DOI: 10.1016/bs.vh.2016.02.004. View

10.

Stern Y . Cognitive reserve in ageing and Alzheimer's disease. Lancet Neurol. 2012; 11(11):1006-12. PMC: 3507991. DOI: 10.1016/S1474-4422(12)70191-6. View

11.

Fleisher A, Grundman M, Jack Jr C, Petersen R, Taylor C, Kim H . Sex, apolipoprotein E epsilon 4 status, and hippocampal volume in mild cognitive impairment. Arch Neurol. 2005; 62(6):953-7. DOI: 10.1001/archneur.62.6.953. View

12.

Simonovitch S, Schmukler E, Bespalko A, Iram T, Frenkel D, Holtzman D . Impaired Autophagy in APOE4 Astrocytes. J Alzheimers Dis. 2016; 51(3):915-27. DOI: 10.3233/JAD-151101. View

13.

Decourt B, Lahiri D, Sabbagh M . Targeting Tumor Necrosis Factor Alpha for Alzheimer's Disease. Curr Alzheimer Res. 2016; 14(4):412-425. PMC: 5328927. DOI: 10.2174/1567205013666160930110551. View

14.

Liu M, Paranjpe M, Zhou X, Duy P, Goyal M, Benzinger T . Sex modulates the ApoE ε4 effect on brain tau deposition measured by F-AV-1451 PET in individuals with mild cognitive impairment. Theranostics. 2019; 9(17):4959-4970. PMC: 6691387. DOI: 10.7150/thno.35366. View

15.

Zeldich E, Chen C, Colvin T, Bove-Fenderson E, Liang J, Tucker Zhou T . The neuroprotective effect of Klotho is mediated via regulation of members of the redox system. J Biol Chem. 2014; 289(35):24700-15. PMC: 4148892. DOI: 10.1074/jbc.M114.567321. View

16.

Shi Y, Yamada K, Liddelow S, Smith S, Zhao L, Luo W . ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy. Nature. 2017; 549(7673):523-527. PMC: 5641217. DOI: 10.1038/nature24016. View

17.

Li G, Bien-Ly N, Andrews-Zwilling Y, Xu Q, Bernardo A, Ring K . GABAergic interneuron dysfunction impairs hippocampal neurogenesis in adult apolipoprotein E4 knockin mice. Cell Stem Cell. 2009; 5(6):634-45. PMC: 2992822. DOI: 10.1016/j.stem.2009.10.015. View

18.

Chen Y, Strickland M, Soranno A, Holtzman D . Apolipoprotein E: Structural Insights and Links to Alzheimer Disease Pathogenesis. Neuron. 2020; 109(2):205-221. PMC: 7931158. DOI: 10.1016/j.neuron.2020.10.008. View

19.

Tank R, Ward J, Celis-Morales C, Smith D, Flegal K, Lyall D . Testing for Interactions Between APOE and Klotho Genotypes on Cognitive, Dementia, and Brain Imaging Metrics in UK Biobank. J Alzheimers Dis. 2021; 83(1):51-55. DOI: 10.3233/JAD-210181. View

20.

Sclan S, Reisberg B . Functional assessment staging (FAST) in Alzheimer's disease: reliability, validity, and ordinality. Int Psychogeriatr. 1992; 4 Suppl 1:55-69. DOI: 10.1017/s1041610292001157. View